BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, March 22, 2026
See today's BioWorld Asia
Home
» 'A Product They Can't Refuse'; Actelion Adding to PAH Market
To read the full story,
subscribe
or
sign in
.
'A Product They Can't Refuse'; Actelion Adding to PAH Market
May 9, 2012
By
Nuala Moran
LONDON – What a difference a year makes. Twelve months ago Actelion Ltd.'s management was under siege from activist investors, as hedge fund managers Elliott Advisors Ltd. tried to wrest control of the company from its founders and its board.
BioWorld Asia